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Background: Functional assays of lipid particles provide another measure of the effects of combination lipid lowering therapy beyond changes in 
lipid concentrations. We examined the effect of niacin and ezetimibe, when combined with a statin, on functional assays of the atheroprotective HDL 
associated protein paraoxonase 1 (PON1).
Methods: Subjects on statin therapy with known coronary heart disease or with high risk for CHD were studied in a 14 month trial of niacin (2000 
mg/d, N = 75) and ezetimibe (10 mg/d, N = 75)). Blinded analysis was conducted on changes in functional measures of PON1, paraoxonase 1 
activity and arylesterase activity on apoprotein concentrations and carotid IMT between therapy.
Results: Baseline levels of paraoxonase and arylesterase activity were similar between treatment groups. There was no change observed in 
paraoxonase or arylesterase activity with niacin but significant reductions in both activity were observed with ezetimide (Figure). Both treatments 
showed moderate to strong bivariate relationships between changes in paraoxonase and arylesterase activities, and apolipoprotein A1 and A2 
concentrations (r = 0.4-0.7; p<0.001 for all), although correlation coefficients tended to be higher with ezetimibe. Changes in paraoxonase and 
arylesterase activity were unrelated to CIMT.
Conclusions: Paraoxonase and arylesterase activity, functional measures of the atheroprotective HDL associated protein PON1, are significantly 
reduced by ezetimibe and unchanged by niacin.
